DV
Dividend Vision

URGN — UroGen Pharma Ltd.

UroGen Pharma Ltd. (URGN)

Total return is 244.9% over the past 9.3 years, 31.0 points behind SPY at 275.9%. Its deepest 1-year drawdown was 42.2%.

URGN is a healthcare equity stock focused on the pharmaceutical sector. The fund does not currently distribute dividends, making it unsuitable for income-focused investors seeking regular payouts. This holding appeals primarily to growth-oriented investors seeking exposure to specialized pharmaceutical companies rather than those prioritizing current yield.

URGN key facts

Asset type
Stock
Asset class
Equity
Inception date
05/04/2017
Distribution frequency
None
Last close
$48.22
Market cap
$2,349,360,384
Average volume
458100.0
Beta
1.575
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.97